Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals Inc    REGN

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Regeneron: Sanofi Plans to Increase Stake to Over $500 Million of Stock

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/11/2013 | 04:44pm CEST
   By Melodie Warner 
 

Regeneron Pharmaceuticals Inc. (>> Regeneron Pharmaceuticals Inc) said Sanofi S.A. (SNY, SAN.FR) notified the biopharmaceutical company of its intent to boost its investment in the company and push its ownership of voting securities to more than $500 million.

Sanofi currently holds about 17% of Regeneron's shares outstanding, according to FactSet Research.

Regeneron said a December 2007 investor agreement bonds the French drug maker to certain standstill provisions, including an agreement not to acquire more than 30% of Regeneron's Class A stock and common stock outstanding.

Regeneron said these standstill provisions are in effect until the fifth anniversary of the expiration of a license and collaboration agreement between the companies.

Sanofi and Regeneron have worked together on experimental cancer drug Zaltrap, among other things.

Shares of Regeneron rose 5.6% to $175.13 in recent trading and have climbed 24% in the past three months.

Write to Melodie Warner at [email protected]

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Regeneron Pharmaceuticals Inc
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on REGENERON PHARMACEUTICALS
07:01a SANOFI : and Regeneron Receive CHMP Positive Opinion for Kevzara® (sarilumab) to..
04/20 REGENERON PHARMACEUTICALS : Studies from Regeneron Pharmaceuticals Inc. Further ..
04/20 REGENERON PHARMACEUTICALS : Data on Hyperglycemia Discussed by Researchers at Re..
04/18 Lilly and Incyte`s Loss Is AbbVie and Regeneron`s Gain
04/14 REGENERON PHARMACEUTICALS : to Report First Quarter 2017 Financial and Operating..
04/13 REGENERON PHARMACEUTICALS : Announces Evinacumab has Received FDA Breakthrough T..
04/06 REGENERON PHARMACEUTICALS : and Sanofi Announce FDA Approval of DUPIXENT® dupilu..
04/06 REGENERON PHARMACEUTICALS : Announces Evinacumab has Received FDA Breakthrough T..
04/04 REGENERON PHARMACEUTICALS : Michael S. Brown Sells 1,000 Shares of Regeneron Pha..
03/31 REGENERON PHARMACEUTICALS : `s Game-Changing New Eczema Drug Could Be a Blockbus..
More news
Sector news : Bio Therapeutic Drugs
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
04/18DJACTELION : J&J Lifts Forecast on Actelion Tie-Up--Update
04/18DJJOHNSON & JOHNSON : Lifts Forecast on Actelion Tie-Up
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug -- Up..
04/14DJELI LILLY AND : FDA Rejects Eli Lilly and Incyte Rheumatoid-Arthritis Drug
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
04/21 Medicare Drug Price Debate Puts Regeneron At Risk
04/20 3 THINGS IN BIOTECH YOU SHOULD LEARN : April 20, 2017
04/17 MAYBE THE WORLD SHOULD SPEND MORE ON : Implications
04/17 WALL STREET BREAKFAST : Geopolitical Concerns Weigh On Markets
04/16 The pharma landscape is shifting - Barron's
Advertisement
Financials ($)
Sales 2017 5 488 M
EBIT 2017 2 102 M
Net income 2017 1 011 M
Finance 2017 1 550 M
Yield 2017 -
P/E ratio 2017 43,46
P/E ratio 2018 34,25
EV / Sales 2017 6,87x
EV / Sales 2018 6,03x
Capitalization 39 263 M
More Financials
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals  Technical Analysis Chart | REGN | US75886F1075 | 4-Traders
Full-screen chart
Technical analysis trends REGENERON PHARMAC...
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 416 $
Spread / Average Target 13%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Leonard S. Schleifer President, Chief Executive Officer & Director
P. Roy Vagelos Chairman
Robert E. Landry Chief Financial Officer & Senior VP-Finance
George Damis Yancopoulos Director & Chief Scientific Officer
Neil Stahl Executive VP-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTIC..0.83%39 263
AMGEN, INC.9.71%118 044
CELGENE CORPORATION5.62%95 114
GILEAD SCIENCES, INC.-7.93%86 186
ACTELION LTD26.98%30 294
VERTEX PHARMACEUTICALS..58.41%28 993
More Results